37th week of 2008 patent applcation highlights part 50 |
Patent application number | Title | Published |
20080221107 | Therapeutic Agents - Compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them. | 2008-09-11 |
20080221108 | Anthranilic Acid Derivatives As Hm74A Receptor Agonists - Therapeutically active anthranilic acid derivatives of Formula (I) wherein R | 2008-09-11 |
20080221109 | PESTICIDAL SUBSTITUTED THIOETHERS - The invention relates to the use of thioether derivatives of formula (I) wherein: R | 2008-09-11 |
20080221110 | Compounds - Tricyclic nitrogen containing compounds and their use as antibacterials | 2008-09-11 |
20080221111 | Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative - The invention describes the use of a PDE4 inhibitor in combination with BH4 or a BH4 derivative for the prevention and/or treatment of respiratory diseases. | 2008-09-11 |
20080221112 | New utilities of amide compounds - Compounds having an activity to enhance the expression of apoAI are provided, which are used as medicaments. | 2008-09-11 |
20080221113 | SUBSTITUTED HEXAHYDROPYRAZINO [1,2-A] PYRIMIDINE-4,7-DIONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS - Substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | 2008-09-11 |
20080221114 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same - A compound of the following formula (I): | 2008-09-11 |
20080221115 | Use of long-chain alcohol derivatives for the treatment of alopecia areata - Disclosed is a method of treating alopecia greata using a compound having the formula: | 2008-09-11 |
20080221116 | ISOXAZOLINE ALPHA 1a/1d ADRENORECEPTOR ANTAGONISTS - The present invention relates to isoxazolines useful as selective α | 2008-09-11 |
20080221117 | UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS - Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity. | 2008-09-11 |
20080221118 | Tetrahydroquinoline Derivatives - Compounds of the formula I, in which s, k, I, W, R | 2008-09-11 |
20080221119 | PYRROLO-PYRIDINE KINASE MODULATORS - The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity. | 2008-09-11 |
20080221120 | Modulation of Aquaporin in Modulation of Angiogenesis and Cell Migration - The invention provides compositions, pharmaceutical preparations, and methods for modulating angiogenesis and/or cell migration in a subject having a cellular proliferative disease (e.g., cancer), or a disease or condition amenable to treatment by enhancing cellular proliferation and cell migration (e.g., angiogenesis), by modulating the activity of an aquaporin, such as aquaporin-1. The compositions and pharmaceutical preparations of the invention may comprise one or more of compounds that modulate the activity of aquaporin-1. | 2008-09-11 |
20080221121 | Controlled release sterile injectable aripiprazole formulation and method - A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided. | 2008-09-11 |
20080221122 | ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE - Compounds represented by the following structure (II) are disclosed: | 2008-09-11 |
20080221123 | Piperazinone Compounds as Anti-Tumor and Anti-Cancer Agents and Methods of Treatment - The present invention relates to piperazinone compounds, pharmaceutical compositions containing those compounds and methods of treating tumors and cancer, among other disease states and conditions in mammalian patients, especially including humans. | 2008-09-11 |
20080221124 | Ethanolamine Salt of N- (3-Methoxy-5-Methylpyrazin-2Yl) -2- (4-[1, 3, 4-Oxadiazole-2-Yl] Phenyl) Pyridine-3-Sulphonamide - N-(Methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-yl]phenyl)pyridine-3-sulphonamide ethanolamine salt its synthesis and its uses are described. | 2008-09-11 |
20080221125 | NOVEL HETEROCYCLIC BENZO[C]CHROMENE DERIVATIVES USEFUL AS MODULATORS OF THE ESTROGEN RECEPTORS - The present invention is directed to novel heterocyclic benzo[c]chromene derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as hot flashes, vaginal dryness, osteopenia and osteoporosis; hormone sensitive cancers and hyperplasia of the breast, endometrium, cervix and prostate; endometriosis, uterine fibroids, osteoarthritis and as contraceptive agents, alone or in combination with a progestogen or progestogen antagonist. | 2008-09-11 |
20080221126 | Use of Hdac Inhibitors for the Treatment of Myeloma - The present invention relates to the use of an HDAC inhibitor, especially an HDAC inhibitor of formula I, | 2008-09-11 |
20080221127 | PPAR ACTIVE COMPOUNDS - Compounds are described that are active on at least one of PPARα, PPARδ, and PPARγ, which are useful for therapeutic and/or prophylactic methods involving modulation of at least one of PPARα, PPARδ, and PPARγ. | 2008-09-11 |
20080221128 | Metalloprotease inhibitors containing a squaramide moiety - The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds with a squaramide or benzoxazinone moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors. | 2008-09-11 |
20080221129 | New compounds - The present invention relates to compounds of the formula (I): | 2008-09-11 |
20080221130 | Fungicidal 5-Methyl-6-Phenylpyrazolopyrimidin-7-Ylamines - 5-Methyl-6-phenylpyrazolopyrimidin-7-ylamines of the formula I | 2008-09-11 |
20080221131 | THIENOPYRIMIDINEDIONES AND THEIR USE IN MODULATION OF AUTOIMMUNE DISEASE - The invention relates to thienopyrimidinediones of formula (I): | 2008-09-11 |
20080221132 | Multi-Functional Small Molecules as Anti-Proliferative Agents - The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival. | 2008-09-11 |
20080221133 | Compounds - The present invention relates to a compound according to Formula (I) | 2008-09-11 |
20080221134 | 8-ALKYNYLXANTHINES AND DERIVATIVES - Disclosed are novel compounds of the general formula (Ia), and pharmaceutically acceptable salts, isomers, diastereomers or enantiomers thereof | 2008-09-11 |
20080221135 | COMBINATION THERAPY - This invention relates to a combination of anti-cancer compounds which comprises a) an orally effective taxane, and b) a thymidylate synthase inhibitor, and optionally at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use. | 2008-09-11 |
20080221136 | Novel Pyrrolo [3,2-D]Pyrimidin-4-One Derivatives And Their Use In Therapy - There are disclosed novel compounds of formula (I) wherein R | 2008-09-11 |
20080221137 | Quinazolines useful as modulators of voltage gated ion channels - The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 2008-09-11 |
20080221138 | Method of using SAHA and Erlotinib for treating cancer - The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor such as suberoylanilide hydroxamic acid (SAHA), or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of one or more anti-cancer agents, including Erlotinib. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic. | 2008-09-11 |
20080221139 | Novel Compounds - The invention provides compounds of formula (I): | 2008-09-11 |
20080221140 | 1-[2',3' -Dideoxy-3' C-(Hydroxymethyl) - Beta-D-Erythro-Pentofuranosyl] Cytosine Derivatives as Hiv - Compounds of the formula (I) wherein: R | 2008-09-11 |
20080221141 | Spirocyclic Cyclohexane Compounds Useful To Treat Substance Dependency - Spirocyclic cyclohexane compounds useful in pharmaceutical compositions for use in the treatment of substance dependency. | 2008-09-11 |
20080221142 | EFTU INHIBITORS OR AMINOTHIAZOLES AND THEIR USES - The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of diseases. | 2008-09-11 |
20080221143 | Morphine and Morphine Precursors - Methods and materials related to the use of morphine, morphine precursors (e.g., reticuline), and inhibitors of morphine synthesis or activity to treat diseases, to reduce inflammation, or to restore normal function are provided. | 2008-09-11 |
20080221144 | Controlled Release Formulations - The present invention relates to controlled release transmucosal formulations which mediate absorption and methods of use comprising a pharmaceutically active agent, preferably morphine, and a water soluble polymer, chitosan, and preferably one more antioxidants, one or more antimicrobial agents, and water. | 2008-09-11 |
20080221145 | Pyrroloquinoline quinone drugs for treatement of cardiac injury and methods of use thereof - The invention includes compositions comprising substantially purified pyrroloquinoline quinone, that are useful in methods for the treatment and prevention of cardiac injury caused by hypoxia or ischemia. The invention also includes methods for the treatment and prevention of cardiac injury comprising contacting a composition of the invention with a human patient. | 2008-09-11 |
20080221146 | INHIBITORS OF NUCLEOPHOSMIN (NPM) AND METHODS FOR INDUCING APOPTOSIS - Nucleophosmin inhibitors are disclosed which inhibit the multimerization of nucleophosmin and the biological activity of nucleophosmin, such as the ability of nucleophosmin to inhibit apoptosis and inhibit cellular differentiation. These small molecule inhibitors are useful for treating diseases and disorders, such as cancer associated with dysregulated nucleophosmin expression. Methods for identifying small molecule inhibitors of nucleophosmin involving multimerization sites for nucleophosmin are also disclosed. An exemplary small molecule inhibitor of nucleophosmin is NSC348884 which has the following chemical structure: | 2008-09-11 |
20080221147 | Method of inhibiting neurotrophin-receptor binding - The present invention relates to compositions which inhibit the binding of nerve growth factor to the p75 | 2008-09-11 |
20080221148 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR - Compounds active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. | 2008-09-11 |
20080221149 | Novel 2-Heteroaryl Substituted Benzothiophenes and Benzofuranes 709 - The present invention relates to novel 2-heteroaryl substituted benzothiophene and benzofuran derivatives, precursors thereof, and therapeutic uses of such compounds, having the structural formula (Ia) below: | 2008-09-11 |
20080221150 | Prevention of Neurodegeneration by Macrolide Antibiotics - The present disclosure describes the use of macrolide antibiotics to prevent neurodegeneration and to treat or prevent disease and conditions which involve neurodegeneration. While not being limited to a specific mechanism of action, in one embodiment, the macrolide antibiotics inhibit neurodegeneration caused by lysosomal and/or mitochondrial dysfunction. The present disclosure contemplates the use of any macrolide antibiotic and pharmaceutically acceptable derivatives thereof. In a specific embodiment, the macrolide antibiotics include bafilomycin A1, bafilomycin B1 and concanamycin. | 2008-09-11 |
20080221151 | 3-AMINO-2-PHENYLPYRROLIDINE DERIVATIVES - 3-amino-2-phenylpyrrolidine compounds useful as NK-1 antagonists, with pharmaceutical compositions and methods of treatment comprising same, are disclosed. | 2008-09-11 |
20080221152 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS - Compounds of Formula 1 | 2008-09-11 |
20080221153 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS -
Compounds represented by Formula (I):
| 2008-09-11 |
20080221154 | HIV-INTEGRASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THEIR USE - Bicyclic hydroxamate compounds represented by the Formula I: | 2008-09-11 |
20080221155 | Novel quinuclidine derivatives and medicinal compositions containing the same - A compound according to formula (I) | 2008-09-11 |
20080221156 | STABLE FORMULATIONS OF ACE INHIBITORS, AND METHODS FOR PREPARATION THEREOF - The present invention provides stable formulations of ACE inhibitors, especially enalapril maleate, that can be manufactured in a time efficient, cost effective manner. Such formulations can be prepared simply and on a large industrial scale. The present invention also provides methods for the preparation of stable formulations of ACE inhibitors, especially enalapril maleate. | 2008-09-11 |
20080221157 | Amide Derivatives as Inhibitors of Histone Deacetylase - The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases. | 2008-09-11 |
20080221158 | Novel 14 and 15 Membered Ring Compounds - The present invention relates to 15-membered macrolides substituted at the 4″ position of formula (I) | 2008-09-11 |
20080221159 | Inhibitors of human immunodeficiency virus replication - Compounds of formula I: | 2008-09-11 |
20080221160 | SULFONYLATED HETEROCYCLES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR - Compounds of the following structure are provided, wherein n, R | 2008-09-11 |
20080221161 | HETEROCYCLIC MODULATORS OF TGR5 FOR TREATMENT OF DISEASE - Disclosed herein are compounds useful as modulators of TGR5 and methods for the treatment or prevention of metabolic, cardiovascular, and inflammatory diseases. | 2008-09-11 |
20080221162 | Monohydrochloride Salt of 1-[3-[3-(4-Chlorophenyl) Propoxy] Propyl] -Piperidine - The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound. | 2008-09-11 |
20080221163 | Selective Estrogen Receptor Modulators - The present invention relates to a selective estrogen receptor modulator of formula I: I; or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma. | 2008-09-11 |
20080221164 | Inhibitors of Sodium Glucose Co-Transporter 2 and Methods of Their Use - Compounds and pharmaceutical compositions comprising them are disclosed that may be useful for the treatment of diseases and disorders such as diabetes and obesity. | 2008-09-11 |
20080221165 | Use of Octenidine Dihydrochloride in Semisolid Preparations - The invention relates to the use of octenidine dihydrochloride for manufacturing a semisolid pharmaceutical composition for the treatment of wounds, atopic dermatitides, infected eczemas, dermatomycoses, vaginal infections, acne, herpes and/or for controlling multidrug-resistant pathogens, where the composition comprises from 0.005 to 5% by weight octenidine dihydrochloride, and a corresponding composition. | 2008-09-11 |
20080221166 | AMINOAMIDES AS OREXIN ANTAGONISTS - The present invention relates to compounds of formula I | 2008-09-11 |
20080221167 | Selective Insecticides Based on Haloalkylnicotinic Acid Derivatives, Anthranilic Acid Diamides, or Phthalic Acid Diamides and Safeners - The present invention relates to the use of selective insecticidal compositions, characterized by an effective amount of an active compound combination comprising | 2008-09-11 |
20080221168 | N-Thio-Anthranilamid Compounds and Their Use as Pesticides - N-Thio-anthranilamid compounds of Formula (I) wherein is a group selected from A1 and A2 wherein the variables and the indices are as defined per the description, processes for preparing the compounds (I), pesticidal compositions comprising compounds (I), use of compounds (I) for the control of insects, acarids or nematodes, and methods for treating, controlling, preventing or protecting animals against infestation or infection by parasites by use of compounds of Formula (I). | 2008-09-11 |
20080221169 | AQUAPORIN MODULATORS AND METHODS OF USING THEM FOR THE TREATMENT OF EDEMA AND FLUID IMBALANCE - Compounds, including 3-carboxy aryl sulfonamide compounds, which agonize or antagonize aquaporin channels and methods of using them to treat disorders or diseases mediated by aquaporins. | 2008-09-11 |
20080221170 | DROXIDOPA AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF FIBROMYALGIA - The present invention provides methods of treating fibromyalgia or other diseases or conditions causing widespread pain and/or fatigue. In particular, the invention provides pharmaceutical compositions comprising droxidopa alone, or in combination with one or more further active agents, that can be used in the inventive methods. The methods of treatment can comprise treating, preventing, reducing, or eliminating a variety of symptoms recognized as indicative of fibromyalgia, such as chronic pain, allodynia, hyperalgesia, fatigue, sleep disturbance, and depression. | 2008-09-11 |
20080221171 | Phenylaminopyridines - The invention relates to novel substituted 3-phenylamino-5-(3-aminophenyl)pyridines and corresponding pyrazines of formula (I), wherein A is CH, C-lower alkyl or N, R | 2008-09-11 |
20080221172 | Use of Quaternary Pyridinium Compounds for Vasoprotection and/or Hepatoprotection - The invention relates to a method for the treatment or prevention of diseases or conditions associated with vascular endothelium dysfunction or liver injury comprising the administration to a patient in a need of such treatment or prevention of a therapeutically or prophylactically effective amount of a compound selected from the group consisting of: | 2008-09-11 |
20080221173 | PHARMACEUTICAL COMPOSITION AND A PROCESS THEREOF - The present invention relates to a pharmaceutical composition having dopaminergic activity and other related pharmaceutical activities comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s); a process of preparing a pharmaceutical composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s), optionally along with excipients(s), wherein the process comprising steps of: (a) extracting a clear solution containing trigonelline and 4-hydroxyisoleucine from plant source; and (b) optionally precipitating derivative(s) of trigonelline and 4-hydroxyisoleucine from the clear solution and obtaining said composition; and an in-vitro method to increase levels of dopamine or to inhibit prolactin by allowing composition comprising trigonelline or its derivative(s) and 4-hydroxyisoleucine or its derivative(s) to bind to cell receptors. | 2008-09-11 |
20080221174 | CONTROLLED RELEASE NISOLDIPINE COMPOSITIONS - Controlled release oral dosage formulations containing calcium channel blockers, and methods of use thereof, are provided for the once-a-day treatment of cardiovascular disorders, such as hypertension, angina, and cardiac arrhythmia. The active agent is preferably a dihydropyridine calcium channel blocker, such as nisoldipine. The formulation provides an increase in the bioavailability of the calcium channel blocker as compared to the bioavailability of the calcium channel blocker in other drug delivery formulations known in the art. In one embodiment, the formulation provides an increase in the bioavailability of the calcium channel blocker, nisoldipine, as compared to the same dose of nisoldipine in the coat-core version of the drug (SULAR®). The formulation can be in the form of a trilayer tablet containing a core or central layer and one or more barrier layers. | 2008-09-11 |
20080221175 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases - The present invention provides N-cyclohexyl benzamide and benzeneacetamide compounds according to formula (I): | 2008-09-11 |
20080221176 | Chemical Compounds - This invention relates to compounds that are modulators of the liver X receptors (LXRs), and also to the methods for the making and use of such compounds. | 2008-09-11 |
20080221177 | 4- PIRIDINYLMETHYLSULPHONAMIDE DERIVATIVE AS FUNGICIDAL PLANT PROTECTION AGENTS - Sulfonamides of the formula I | 2008-09-11 |
20080221178 | Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof - Compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein R | 2008-09-11 |
20080221179 | SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators - The present invention relates to compounds of Formula (I), | 2008-09-11 |
20080221180 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2008-09-11 |
20080221181 | COMPOUNDS FOR TREATING TUMORS - The invention provides compounds of formula (I): | 2008-09-11 |
20080221182 | ANTI-CANCER AND ANTI-MICROBIAL OXAZOLIDINONES - Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity. | 2008-09-11 |
20080221183 | ANTI-CANCER AND ANTI-MICROBIAL OXAZOLIDINONES - Disclosed herein are various novel oxazolidinone, imidazolidinone, and thiazolidinone analogs and methods of treating cancer and/or microbial infection using these analogs. Particular 4-oxazolidinone compounds are shown to have anti-cancer and anti-microbial activity. | 2008-09-11 |
20080221184 | Combined agents for treatment of glaucoma - A pharmaceutical composition for the treatment of glaucoma which comprises an angiotensin II antagonist and a prostaglandin which is unoprostone or latanoprost, and a method for treatment of glaucoma by administering the composition to a patient. | 2008-09-11 |
20080221185 | Glyt1 Transporter Inhibitors and Uses Thereof in Treatment of Neurological and Neuropsychiatric Disorders - The invention provides a compound of formula (I) or a solvate thereof: | 2008-09-11 |
20080221186 | 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds - Compounds of Formula 1 | 2008-09-11 |
20080221187 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors -
Compounds represented by Formula (I):
| 2008-09-11 |
20080221188 | New Benzimidazole Derivatives - Provided herein are compounds in accord with Formula I: | 2008-09-11 |
20080221189 | Use of Metronidazole For Preparing a Pharmaceutical Composition For Treating Pathologies Related to the B-Type Receptor of Interleukin 8 and/or to a Pacap Type 1 Receptor - The invention relates to use of metronidazole for the preparation of a pharmaceutical composition for treating pathologies involving at least one receptor chosen from the group comprising the IL-8RB receptor and the PAC-1 receptor. | 2008-09-11 |
20080221190 | High Purity Butoconazole Nitrate with Specified Particle Size and a Process for the Preparation Thereof - One object of the invention is high purity butoconazole nitrate of the formula (I) (I) containing maximum 0.1 wt % of chemical impurities, wherein at least 95% of the particles of the substance are below 75pm by diameter, whereas at least 99% of the particles are below 250 μm by diameter, and process for its preparation. A pharmaceutical composition comprising as active ingredient, high purity butoconazole nitrate of specified particle size in admixture with known auxiliaries is also within the scope of | 2008-09-11 |
20080221191 | Cationic substituted benzofurans as antimicrobial agents - A method of treating a | 2008-09-11 |
20080221192 | Compounds and Compositions as Protein Kinase Inhibitors - The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, Bcr-Abl, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC kinases. | 2008-09-11 |
20080221193 | 3-AMINO CHROMANE DERIVATIVES - The present invention relates to 3-amino chromane derivatives; to compositions containing such compounds; to methods of synthesizing such compounds; and to methods of using such compounds and compositions containing such compounds in the treatment of serotonin disorders, such as depression and anxiety. | 2008-09-11 |
20080221194 | Novel Potassium channel Blockers and Uses Thereof - The invention relates to compounds of Formula (1) for use in modulating potassium channel activity in cells. | 2008-09-11 |
20080221195 | 1,2-DIARYLACETYLENE DERIVATIVES OF ACYLTRYPTOPHANOLS - The present invention relates to acyltryptophanols of the general formula I, | 2008-09-11 |
20080221196 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES - Isoindolin-1-one and Isoindoline-1,3-dione substituted in the 2-position with an α-(3,4-disubstituted phenyl)alkyl group and in the 4- and/or 5-position with a nitrogen-containing group are inhibitors of, and thus useful in the treatment of disease states mediated by, TNFα and phosphodiesterase. A typical embodiment is 2-[1-(3-ethoxy-4-methoxyphenyl)2-methylsulfonylethyl]4,5-diaminoisoindoline-1,3-dione. | 2008-09-11 |
20080221197 | INDOLE ANTAGONISTS OF P2Y1 RECEPTOR USEFUL IN THE TREATMENT OF THROMBOTIC CONDITIONS - The present invention provides indole compounds of Formula (I) or (II): | 2008-09-11 |
20080221198 | Novel Crystalline Forms of Antidiabetic Compounds - Novel crystalline forms of two indole compounds connected to phenoxyalkylcarboxylic acid groups are selective PPAR gamma partial agonists that are useful in the treatment of type 2 diabetes, hyperglycemia, obesity, dyslipidemia, and the metabolic syndrome. The novel crystal forms include a crystalline free acid dihydrate and crystalline free acid anhydrate of one compound and several crystalline forms of the free acid and the sodium salt of the second compound. The invention also relates to pharmaceutical compositions comprising these novel crystal forms, processes to prepare the crystal forms and their pharmaceutical compositions, and uses of the crystal forms in the treatment of type 2 diabetes and other PPAR gamma modulated diseases. | 2008-09-11 |
20080221199 | METHOD FOR IMPROVING MEMORY IN MAMMALS - A method for improving memory in healthy subjects is disclosed. This method makes use of melatonin receptor antagonists such as luzindole and/or K-185 to reverse the inhibitory effect of melatonin. This invention is particularly relevant among subjects that do not show signs of central nervous system disorders and wish to improve their cognitive performance, especially in tasks. | 2008-09-11 |
20080221200 | Combination of Organic Compounds - The present invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising of a DPP IV inhibitor or a pharmaceutically acceptable salt thereof and comprising at least one immunosuppressive or immunomodulator agent, or a pharmaceutically acceptable salt thereof. | 2008-09-11 |
20080221201 | ARYL SULFONAMIDES USEFUL FOR MODULATION OF THE PROGESTERONE RECEPTOR - In one embodiment, compounds of the following structure are described, wherein R | 2008-09-11 |
20080221202 | STEROIDS DERIVATIVES AS SELECTIVE PROGESTERONE RECEPTOR MODULATORS - The present invention is directed to novel steroid derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor. | 2008-09-11 |
20080221203 | Use of Agonists and Antagonists of Beta Adrenoceptors for Treating Arterial Disease - Methods for treating and/or preventing cardiovascular diseases and diseases related thereto by administering a therapeutically effective amount of one or more first compound(s) having a beta3-adrenoceptor agonistic effect and a therapeutically effective amount of one or more second compound(s) having a beta1/beta2-adrenoceptor antagonistic effect are disclosed. The first compound(s) and the second compound(s) are used simultaneously, separately or sequentially as a combined preparation. Related cardiovascular diseases include arterial diseases, ischemic and failing cardiac diseases, including heart failure, conditions related to metabolic syndrome or angiogenesis-related disease. Pharmaceutical compositions are also described. | 2008-09-11 |
20080221204 | Materials and Methods for Treating Coagulation Disorders - This invention is drawn to compounds which are more easily metabolized by the metabolic drug detoxification systems. Particularly, warfarin analogs which have been designed to include esters within the structure of the compounds are taught. The invention teaches methods of reducing the toxicity of drugs comprising the introduction of ester groups into drugs during the synthesis of the drug. This invention is also drawn to methods of treating coagulation disorders comprising the administration of compounds which have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester containing warfarin, analogs are also taught. | 2008-09-11 |
20080221205 | FURAN DERIVATIVES FOR PREVENTING AND CURING OSTEOPOROSIS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - The present invention relates to furan derivatives and pharmaceutical compositions containing them to prevent and cure osteoporosis. The furan derivatives of the present invention have effect on bone proliferation with the side effect reduced, so that they can be used for bone disease. | 2008-09-11 |
20080221206 | Compounds Derived From Lidocaine, Pharmaceutical Compositions, Use And Method Of Treatment, Prevention Or Inhibition Of Disease - The present invention relates to lidocaine derived compounds, which present less anesthetic activity than lidocaine itself, but with more anti-inflammatory and spasmolytic activity than said lidocaine as well as pharmaceutical compositions with at least one of these compounds or a salt of those as active principle and to the use of such compositions to treat, prevent or inhibit atopic diseases including asthma, rhinitis, allergic urticaria, chronic lung inflammation associated with eosinophilia, following the example of atopic asthma and chronic intestinal inflammation, as colitis for instance. The pharmaceutical composition may be available in spray form, solution, suspension, emulsion destinated to be applied by nebulization, or in any of the pharmaceutical available forms for oral or injectable use. | 2008-09-11 |